重组干扰素α-2b栓联合保妇康栓治疗宫颈高危型乳头瘤病毒亚临床感染疗效观察被引量：5

导出

摘要目的:观察重组干扰素α-2b栓联合保妇康栓治疗宫颈高危型乳头瘤(HPV)病毒亚临床感染的临床疗效。方法:选取宫颈高危型HPV亚临床感染患者70例,随机分为联合组和对照组,各35例。联合组予以重组人干扰素a-2b栓联合保妇康栓,非月经期内交替用药;对照组予以单纯重组人干扰素α-2b栓非月经期内用药治疗。2组疗程均为3月。评估2组患者治疗3月后的临床效果,并比较其高危型HPV清除率。结果:临床总有效率联合组94.29%,对照组77.14%,2组比较,差异有统计学意义(P<0.05)。HPV清除总有效率,联合组88.57%,对照组68.57%,2组比较,差异有统计学意义(P<0.05)。结论:重组干扰素α-2b栓联合保妇康栓治疗宫颈高危型HPV亚临床感染的疗效较确切,能更有效地清除HPV,提高临床效果。

作者吴永茂

机构地区庆元县人民医院妇产科

出处《新中医》 CAS 2015年第9期145-146,共2页 New Chinese Medicine

关键词宫颈乳头瘤病毒高危型亚临床感染重组干扰素α-2b栓保妇康栓

分类号 R711.32 [医药卫生—妇产科学]

引文网络
相关文献

参考文献7

1Carter JR, Ding Z. HPV infection and cervical disease a review[J]. Aust NZJ Obstet Gynaecol, 2011, 51 (2) 103-108.
2Jeong NH, Lee NW, Kim H J, etal. High-risk human papillomavirus testing for monitoring patients treated for high-grade cervical intraepithelial neoplasia[J]. J Qbstet Gynaecol Res, 2009, 35(4): 706-711.
3吕亚淑,陈书玲.高危型人乳头瘤病毒感染宫颈炎治疗方法[J].河北医药,2014,36(17):2592-2594. 被引量：7
4Belinson SE, Belinson JL. Human Papillomavirus DNA Testing for Cervical Cancer Screening: Practical Aspects in Developing Countries [J]. Molecular Diagnosis & Therapy, 2010 14(4): 215-222.
5李健,李红霞.重组人干扰素治疗宫颈HPV感染的临床观察[J].中国优生与遗传杂志,2014,22(11):111-113. 被引量：22
6杨祎,陈冬梅,付纬.保妇康栓联合干扰素α-2b栓剂治疗宫颈人乳头瘤病毒亚临床感染疗效观察[J].海南医学,2012,23(23):54-55. 被引量：11
7黎锐勤,龚宇,艾战秀.保妇康栓联合干扰素α-2b栓剂治疗宫颈人乳头瘤病毒亚临床感染疗效观察[J].吉林医学,2014,35(15):3275-3275. 被引量：7

二级参考文献17

1张胜英,倪琪,贺梅芳.复方莪术油栓治疗宫颈糜烂108例疗效观察[J].抗感染药学,2007,4(2):78-79. 被引量：3
2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量：869
3邵爱琴,张慧,陈有梅.干扰素治疗宫颈糜烂的疗效观察[J].中国妇幼保健,2007,22(26):3666-3667. 被引量：14
4Zur Hausen H. Human papillomaviruses in the pathogenesis of ano- genital cancer [J]. Virology, 1991, 184(1): 9-13.
5Riethmuller D, Schaal JP, Mougin C. Epidemiology and natural his- tory of genital infection by human papilkmavirus [J]. Gynecol Ob- stet Fertil, 2002, 30(2): 139-146.
6Karim R, et al. Human papillomavirus (hpv)upregulates the cellular deubiquitinase uchll to suppress the keratinocyte' s innate immune response[J]. PLoS Pathog, 2013 May, 9 (5) :e1003384.
7Richardson H, et al. The natural history of type-specific human papillomavirus infections in female university students[J]. Cancer Epidemiol Biomarkers Prey, 2003 Jun, 12 (6) :485-490.
8Vlolano M, van den Brule A, Plummer M, et al. Determinants of clearance of human papiUomavirus infections in Colombian women with normal cytology :a population-based, 5-year follow-up study[J]. Am J Epidemiol, 2003, 158 (5) :486-494.
9Wright Jr T C, Massad L S, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests[J]. Am J Obstet Gynecol, 2007, 197 (4) ..346-355.
10Clifford G M, et al. Human papillomavirus types in invasive cervical cancer worldwide :a meta-analysis[J]. Br J Cancer, 2003, 88 ( 1 ) : 63-73.